Bure Equity AB

Latest Results (12.04.2026):

Bure Equity AB — fourth quarter 2024 (and full‑year 2024): In Q4 2024 Bure Equity AB reported a quarterly loss (after tax) of SEK -1,291M (vs profit SEK 2,974M in Q4 2023) while full‑year 2024 delivered strong investment earnings with profit after tax SEK 5,735M (4,749) and earnings per share SEK 77.4 (64.0). Net asset value (NAV) was SEK 333.0 per share at 31 Dec 2024 (SEK 24,689M), down 5.0% in the quarter but up 29.1% for the year; NAV post‑report (19 Feb 2025) was SEK 353.6 per share (+6.2% since year start).

Quarterly & annual bottom line

In Q4 2024 Bure Equity AB reported a loss after tax of SEK -1,291M (Q4 2023: +2,974M). For full‑year 2024 the Group reported profit after financial items SEK 5,735M and profit after tax SEK 5,735M (2023: 4,749), with EPS 77.4 SEK (64.0 SEK).

Net asset value (NAV)

Bure Equity AB’s NAV at 31 Dec 2024 was SEK 333.0 per share (total NAV SEK 24,689M). NAV fell c.5.0% during Q4 2024 (350.3 → 333.0) but rose 29.1% during full‑year 2024. NAV per share on 19 Feb 2025 was reported at SEK 353.6.

Key portfolio drivers

Major positive value drivers for Bure Equity AB in 2024 were Mycronic (+SEK 2,533M), Yubico (shares + warrants: +SEK 2,061M, with an 85% share price rise in 2024), Xvivo Perfusion (+SEK 717M) and Vitrolife (+SEK 437M).

Portfolio composition

At year‑end Bure Equity AB’s reported portfolio split: listed holdings ~85.6% of NAV (SEK 21,125M), unlisted holdings ~11.4% (SEK 2,826M) and treasury/cash ~3.0% (SEK 738M). Total holdings reported SEK 23,951M.

Notable transactions in Q4 / 2024

During 2024 Bure Equity AB acquired 14.5% of Mentimeter for SEK 531M and Bure Growth provided a SEK 17M convertible to BioLamina. Atle (Bure’s subsidiary) made several investments including acquiring 66% of First Fondene AS and increasing ownership in Atle Fund Management. Bure also increased exposure to Cavotec (700,000 shares for SEK 12M).

Dividends, proposal & shareholder return

For 2024 Bure Equity AB received dividends totalling SEK 208M. The Board proposes an ordinary dividend of SEK 2.75 per share (prior year 2.50). Total return on the Bure share for 2024 was reported at 34.5% (SIX RX +8.6%).

Liquidity & treasury

Bure Equity AB reported treasury assets (cash, short‑term investments and other) of SEK 738M at 31 Dec 2024 (down SEK 812M vs 2023). Parent reported net receivables/interest‑bearing assets and limited parent‑level gearing; the Group’s policy is to keep the Parent essentially debt‑free.

Risks & governance highlights

Bure Equity AB reiterated market and geopolitical risk exposure (notably US policy/tariff uncertainty) as potential headwinds for portfolio valuations; the company operates as an IFRS investment entity and values holdings at fair value per the report.